PPARD and arthritic joint disease: Since PPARβ/δ is a negative regulator of NF-κB activity, the inhibition of PPARβ/δ, either chemically or genetically on MSCs, enhanced their therapeutic potential both in vitro and in vivo in an experimental model of arthritis, diminishing the frequency of Th17 cells.